Is inverse association between lipoprotein(a) and diabetes mellitus another paradox in cardiometabolic medicine?

References

• Kannel BW, McGee DL. Diabetes and cardiovascular disease. The framingham study. JAMA. 1979;241(19):2035–2038. doi: 10.1001/jama.241.19.2035
   PubMed Web of Science ®Google Scholar
• Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabet Res Clin Pract. 2014;103(2):137–149. doi: 10.1016/j.diabres.2013.11.002
   PubMed Web of Science ®Google Scholar
• Fowler MJ. Microvascular and Macrovascular Complications of Diabetes. Clin Diabetes. 2008;26(2):77–82. doi: 10.2337/diaclin.26.2.77
   Google Scholar
• Wang CCL, Hess CN, Hiatt WR, et al. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations. Circulation. 2016;133(24):2459–2502. doi: 10.1161/CIRCULATIONAHA.116.022194
   PubMed Web of Science ®Google Scholar
• Haffner SM, Lehto S, Rönnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–234. doi: 10.1056/NEJM199807233390404
   PubMed Web of Science ®Google Scholar
• Dash S, Leiter LA. Residual cardiovascular risk among people with diabetes. Diab Obes Metab. 2019;21(S1):28–38. doi: 10.1111/dom.13646
   PubMedGoogle Scholar
• Bulugahapitiya U, Siyambalapitiya S, Sithole J, et al. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabetic Med. 2009;26(2):142–148. doi: 10.1111/j.1464-5491.2008.02640.x
   PubMed Web of Science ®Google Scholar
• Howard BV, Best LG, Galloway JM, et al. Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care. 2006;29(2):391–397. doi: 10.2337/diacare.29.02.06.dc05-1299
   PubMed Web of Science ®Google Scholar
• Rasouli M, Kiasari AM. Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease. Clin Chem Lab Med. 2008;46(5):667–673. doi: 10.1515/CCLM.2008.137
   PubMed Web of Science ®Google Scholar
• Berg K. A NEW SERUM TYPE SYSTEM in MAN—THE lp SYSTEM. Acta Pathologica Microbiologica Scand. 1963;59(3):369–382. doi: 10.1111/j.1699-0463.1963.tb01808.x
   PubMedGoogle Scholar
• Gurdasani D, Sjouke B, Tsimikas S, et al. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol. 2012;32(12):3058–3065. doi: 10.1161/ATVBAHA.112.255521
   PubMed Web of Science ®Google Scholar
• Mack S, Coassin S, Rueedi R, et al. A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms. J Lipid Res. 2017;58(9):1834–1844. doi: 10.1194/jlr.M076232
   PubMed Web of Science ®Google Scholar
• Nestel P. Lipoprotein(a) Removal Still a Mystery. J Am Heart Assoc. 2019;8(4). doi: 10.1161/JAHA.118.011903
   PubMed Web of Science ®Google Scholar
• Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res. 2008;49(10):2230–2239. doi: 10.1194/jlr.M800174-JLR200
   PubMed Web of Science ®Google Scholar
• Marcovina SM, Navabi N, Allen S, et al. Development and validation of an isoform-independent monoclonal antibody–based Elisa for measurement of lipoprotein(a). J Lipid Res. 2022;63(8):100239. doi: 10.1016/j.jlr.2022.100239
   PubMed Web of Science ®Google Scholar
• Cegla J, France M, Marcovina SM, et al. Lp(a): when and how to measure it. Ann Clin Biochem. 2020;58(1):16–21. doi: 10.1177/0004563220968473
   PubMed Web of Science ®Google Scholar
• Waldeyer C, Makarova N, Zeller T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38(32):2490–2498. doi: 10.1093/eurheartj/ehx166
   PubMed Web of Science ®Google Scholar
• Saeed A, Sun W, Agarwala A, et al. Lipoprotein(a) levels and risk of cardiovascular disease events in individuals with diabetes mellitus or prediabetes: the atherosclerosis risk in communities study. Atherosclerosis. 2019;282:52–56. doi: 10.1016/j.atherosclerosis.2018.12.022
   PubMed Web of Science ®Google Scholar
• Nakamura H, Kataoka Y, Nicholls SJ, et al. Elevated lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: insights from the REASSURE-NIRS registry. Atherosclerosis. 2022;349:183–189. doi: 10.1016/j.atherosclerosis.2022.03.033
   PubMed Web of Science ®Google Scholar
• Takahashi N, Dohi T, Funamizu T, et al. Prognostic impact of lipoprotein (a) on long-term clinical outcomes in diabetic patients on statin treatment after percutaneous coronary intervention. J Cardiol. 2020;76(1):25–29. doi: 10.1016/j.jjcc.2020.01.013
   PubMed Web of Science ®Google Scholar
• Hao Y, Yang Y, Wang Y, et al. Relationship between lipoprotein(a) and revascularization after percutaneous coronary intervention in type 2 diabetes mellitus patients with acute coronary syndrome. Curr Med Res Opin. 2022;38(10):1663–1672. doi: 10.1080/03007995.2022.2078080
   PubMed Web of Science ®Google Scholar
• Lan NSR, Chan DC, Pang J, et al. Lipoprotein(a) in patients with type 2 diabetes and premature coronary artery disease in the coronary care unit. Heart Lung Circ. 2021;30(5):734–740. doi: 10.1016/j.hlc.2020.09.932
   PubMed Web of Science ®Google Scholar
• Silverio A, Cancro FP, Maio M, et al. Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes. J Thromb Thrombolysis. 2022;54(3):382–392. doi: 10.1007/s11239-022-02701-w
   PubMed Web of Science ®Google Scholar
• Markus MRP, Ittermann T, Schipf S, et al. Association of sex-specific differences in lipoprotein(a) concentrations with cardiovascular mortality in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol. 2021;20(1). doi: 10.1186/s12933-021-01363-x
   PubMed Web of Science ®Google Scholar
• Nakhjavani M, Morteza A, Esteghamati A, et al. Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes. Lipids. 2011;46(4):349–356. doi: 10.1007/s11745-010-3513-1
   PubMed Web of Science ®Google Scholar
• Qasim AN, Martin SS, Mehta NN, et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol. 2011;150(1):17–21. doi: 10.1016/j.ijcard.2010.02.021
   PubMed Web of Science ®Google Scholar
• Enkhmaa B, Berglund L. Non-genetic influences on lipoprotein(a) concentrations. Atherosclerosis. 2022;349:53–62. doi: 10.1016/j.atherosclerosis.2022.04.006
   PubMed Web of Science ®Google Scholar
• Ciarambino T, Crispino P, Guarisco G, et al. Gender differences in insulin resistance: new knowledge and perspectives. Curr Issues Mol Biol. 2023;45(10):7845–7861. doi: 10.3390/cimb45100496
   PubMed Web of Science ®Google Scholar
• Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9(5):579–592. doi: 10.1161/01.atv.9.5.579
   PubMedGoogle Scholar
• Nielsen LB, Grønholdt MLM, Schroeder TV, et al. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol. 1997;17(5):905–911. doi: 10.1161/01.atv.17.5.905
   PubMed Web of Science ®Google Scholar
• van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134(8):611–624. doi: 10.1161/circulationaha.116.020838
   PubMed Web of Science ®Google Scholar
• Zhang HW, Zhao W, Guo YL, et al. Elevated lipoprotein (a) levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus. Nutr Metab Cardiovasc Dis. 2018;28(10):980–986. doi: 10.1016/j.numecd.2018.05.010
   PubMed Web of Science ®Google Scholar
• Boras J, Ljubic S, Car N, et al. Lipoprotein(a) predicts progression of carotid artery intima-media thickening in patients with type 2 diabetes: a four-year follow-up. Wien Klin Wochenschr. 2010;122(5–6):159–164. doi: 10.1007/s00508-010-1318-0
   PubMed Web of Science ®Google Scholar
• Wakabayashi I, Masuda H. Lipoprotein (a) as a determinant of arterial stiffness in elderly patients with type 2 diabetes mellitus. Clin Chim Acta. 2006;373(1–2):127–131. doi: 10.1016/j.cca.2006.05.018
   PubMed Web of Science ®Google Scholar
• Real JT, Folgado J, Mendez MM, et al. Plasma homocysteine, Lp(a), and oxidative stress markers in peripheral macroangiopathy in patients with type 2 diabetes mellitus. Clin Investig Arterioscler. 2016;28(4):188–194. doi: 10.1016/j.arteri.2016.05.007
   PubMedGoogle Scholar
• Gazzaruso C, Coppola A, Montalcini T, et al. Lipoprotein(a) and homocysteine as genetic risk factors for vascular and neuropathic diabetic foot in type 2 diabetes mellitus. Endocrine. 2012;41(1):89–95. doi: 10.1007/s12020-011-9544-4
   PubMed Web of Science ®Google Scholar
• Yun JS, Lim TS, Cha SA, et al. Lipoprotein(a) predicts the development of diabetic retinopathy in people with type 2 diabetes mellitus. J Clin Lipidol. 2016;10(2):426–433. doi: 10.1016/j.jacl.2015.12.030
   PubMed Web of Science ®Google Scholar
• Song KH, Ko SH, Kim HW, et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care. 2005;28(7):1718–1723. doi: 10.2337/diacare.28.7.1718
   PubMed Web of Science ®Google Scholar
• Heinrich NS, von Scholten BJ, Reinhard H, et al. Lipoprotein(a) and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria. J Diabetes Complications. 2020;34(7):107593. doi: 10.1016/j.jdiacomp.2020.107593
   PubMed Web of Science ®Google Scholar
• Moosaie F, Firouzabadi FD, Abouhamzeh K, et al. Lp(a) and apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: a case-cohort study. Nutr Metab Cardiovasc Dis. 2020;30(10):1723–1731. doi: 10.1016/j.numecd.2020.05.011
   PubMed Web of Science ®Google Scholar
• Ren X, Zhang Z, Yan Z. Association between lipoprotein (A) and diabetic nephropathy in patients with type 2 diabetes mellitus: a meta-analysis. Front Endocrinol. 2021;12. doi: 10.3389/fendo.2021.633529
   Google Scholar
• Singh SS, Rashid M, Lieverse AG, et al. Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus. Diabetologia. 2020;63(6):1248–1257. doi: 10.1007/s00125-020-05120-9
   PubMed Web of Science ®Google Scholar
• Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004;27(6):1496–1504. doi: 10.2337/diacare.27.6.1496
   PubMed Web of Science ®Google Scholar
• Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713–735. doi: 10.1161/CIRCRESAHA.116.309326
   PubMed Web of Science ®Google Scholar
• Tselepis AD. Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role. J Biomed Res. 2018;31(1):13–22. doi: 10.7555/JBR.31.20160009
   PubMedGoogle Scholar
• Berglund L, Kim K, Zhang W, et al. Lp(a)-associated oxidized phospholipids in healthy black and white participants in relation to apo(a) size, age, and family structure. J Am Heart Assoc. 2021;10(17):20158. doi: 10.1161/JAHA.120.020158
   Web of Science ®Google Scholar
• Pitocco D, Tesauro M, Alessandro R, et al. Oxidative stress in diabetes: implications for vascular and other complications. Int J Mol Sci. 2013;14(11):21525–21550. doi: 10.3390/ijms141121525
   PubMed Web of Science ®Google Scholar
• Byun YS, Lee JH, Arsenault BJ, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015;65(13):1286–1295. doi: 10.1016/j.jacc.2015.01.050
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353(1):46–57. doi: 10.1056/NEJMoa043175
   PubMed Web of Science ®Google Scholar
• Younis N, Sharma R, Soran H, et al. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol. 2008;19(4):378–384. doi: 10.1097/MOL.0b013e328306a057
   PubMed Web of Science ®Google Scholar
• Doucet C, Huby T, Ruiz J, et al. Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo. Atherosclerosis. 1995;118(1):135–143. doi: 10.1016/0021-9150(95)05600-2
   PubMed Web of Science ®Google Scholar
• Zhang J, Ren S, Shen GX. Glycation amplifies lipoprotein(a)-induced alterations in the generation of fibrinolytic regulators from human vascular endothelial cells. Atherosclerosis. 2000;150(2):299–308. doi: 10.1016/s0021-9150(99)00381-0
   PubMed Web of Science ®Google Scholar
• Wang JJ, Gong JB, Li HQ, et al. Lipoprotein(a) complexes with beta2-glycoprotein I in patients with coronary artery disease. J atherosclerosis and thrombosis. 2012;19(1):81–89. doi: 10.5551/jat.9340
   PubMed Web of Science ®Google Scholar
• Wang C, Niu DM, Hu J, et al. Elevated serum β2-glycoprotein-I-lipoprotein(a) complexes levels are associated with the presence and complications in type 2 diabetes mellitus. Diabet Res Clin Pract. 2013;100(2):250–256. doi: 10.1016/j.diabres.2013.03.002
   PubMed Web of Science ®Google Scholar
• F GD, Thorgeirsson G, Sulem P, et al. Lipoprotein(a) concentration and Risks of cardiovascular disease and diabetes. J Am Coll Cardiol. 2019;74(24):2982–2994. doi: 10.1016/j.jacc.2019.10.019
   PubMed Web of Science ®Google Scholar
• Mora S, Kamstrup PR, Rifai N, et al. Lipoprotein(a) and Risk of Type 2 Diabetes. Clin Chem. 2010;56(8):1252–1260. doi: 10.1373/clinchem.2010.146779
   PubMed Web of Science ®Google Scholar
• Liu C, Xu MX, He YM, et al. Lipoprotein (a) is not significantly associated with type 2 diabetes mellitus: cross-sectional study of 1604 cases and 7983 controls. Acta Diabetol. 2017;54(5):443–453. doi: 10.1007/s00592-017-0965-2
   PubMed Web of Science ®Google Scholar
• Paige E, Masconi KL, Tsimikas S, et al. Lipoprotein(a) and incident type-2 diabetes: results from the prospective bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16(1). doi: 10.1186/s12933-017-0520-z
   PubMedGoogle Scholar
• Skoumas I, Andrikou I, Grigoriou K, et al. Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: a 9 year follow-up study. J Clin Lipidol. 2023;17(4):512–8. doi: 10.1016/j.jacl.2023.05.103
   PubMedGoogle Scholar
• Hermans MP, Ahn SA, Rousseau MF. The mixed benefit of low lipoprotein(a) in type 2 diabetes. Lipids Health Dis. 2017;16(1):1–8. doi: 10.1186/s12944-017-0564-9
   PubMedGoogle Scholar
• Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1(3):220–227. doi: 10.1016/S2213-8587(13)70064-0
   PubMed Web of Science ®Google Scholar
• Tolbus A, Mortensen MB, Nielsen SF, et al. Kringle IV type 2, not low lipoprotein(a), as a cause of diabetes: a novel genetic approach using SNPs associated selectively with lipoprotein(a) concentrations or with Kringle IV type 2 repeats. Clin Chem. 2017;63(12):1866–1876. doi: 10.1373/clinchem.2017.277103
   PubMed Web of Science ®Google Scholar
• Neele DM, de Wit ECM, Princen HMG. Insulin suppresses apolipoprotein(a) synthesis by primary cultures of cynomolgus monkey hepatocytes (short communication). Diabetologia. 1999;42(1):41–44. doi: 10.1007/s001250051110
   PubMed Web of Science ®Google Scholar
• l M, Colussi G, Torre MD, et al. Relationships of plasma lipoprotein(a) levels with insulin resistance in hypertensive patients. Metabolism. 2014;63(11):1439–1446. doi: 10.1016/j.metabol.2014.08.007
   PubMed Web of Science ®Google Scholar
• Rainwater DL, Haffner SM. Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype. Arteriosclerosis Thrombosis Vasc Biol. 1998;18(8):1335–1341. doi: 10.1161/01.atv.18.8.1335
   PubMed Web of Science ®Google Scholar
• Sidhu M, Crook D, F GI, et al. Inverse relationship between serum Lp(a) levels and first-phase insulin secretion. Diabetes. 1992;41(10):1341–1345. doi: 10.2337/diab.41.10.1341
   PubMed Web of Science ®Google Scholar
• Buchmann N, Scholz M, Lill CM, et al. Association between lipoprotein(a) level and type 2 diabetes: no evidence for a causal role of lipoprotein(a) and insulin. Acta Diabetol. 2017;54(11):1031–1038. doi: 10.1007/s00592-017-1036-4
   PubMed Web of Science ®Google Scholar
• Andersson C, Lyass A, Larson MG, et al. Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insights from the framingham heart study. Diabetologia. 2015;58(12):2774. doi: 10.1007/s00125-015-3762-x
   PubMed Web of Science ®Google Scholar
• Tsamoulis D, Siountri I, Rallidis LS. Lipoprotein(a): its association with Calcific aortic valve stenosis, the emerging RNA-Related treatments and the hope for a New Era in aortic valve calcification. J Cardiovasc Dev Dis. 2023;10(3):96. doi: 10.3390/jcdd10030096
   PubMed Web of Science ®Google Scholar